Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
YMI024 · 1 trial · 1 indication
Change from baseline in log-transformed Interleukin-6 (IL-6) to evaluate the dose-response relationship using the Multiple Comparison Procedures (MCP) component of the Multiple Comparison Procedure-Modelling (MCP-Mod) methodology
| Arm | Type | Description |
|---|---|---|
| YMI024 Dose 1 | EXPERIMENTAL | Participants receive YMI024 Dose 1 in addition to standard-of-care therapies. |
| YMI024 Dose 2 | EXPERIMENTAL | Participants receive YMI024 Dose 2 in addition to standard-of-care therapies. |
| YMI024 Dose 3 | EXPERIMENTAL | Participants receive YMI024 Dose 3 in addition to standard-of-care therapies. |
| YMI024 Dose 4 | EXPERIMENTAL | Participants receive YMI024 Dose 4 in addition to standard-of-care therapies. |
| YMI024 Dose 5 | EXPERIMENTAL | Participants receive YMI024 Dose 5 in addition to standard-of-care therapies. |
| Placebo | PLACEBO_COMPARATOR | Participants receive a matching placebo in addition to standard-of-care therapies |
| Name | Type | Description |
|---|---|---|
| YMI024 | DRUG | YMI024 in different doses |
| Placebo | DRUG | matching placebo |
Inclusion Criteria: 1. Signed informed consent must be obtained prior to any study specific procedures, and participant able to understand and comply with study requirements. 2. Male and female participants aged between 18-80 years (inclusive) at Screening. 3. Documented stable CAD as evidenced by ...
Top 8 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Ziltivekimab |
| Novartis AG Sponsored ADR | NVS | 4 | PHASE3 | Inclisiran |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| Viatris, Inc. | VTRS | 1 | PHASE3 | Selatogrel |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 1 | - | alirocumab |
YMI024 is an investigational small molecule drug being developed by Novartis AG for the treatment of coronary artery disease. It is currently in Phase 2 clinical development and is being studied in adults with stable coronary artery disease and elevated hsCRP, a marker of inflammation.
YMI024 is being evaluated for use in adults with stable coronary artery disease and elevated hsCRP. The Phase 2 study is designed to assess the efficacy, safety, and tolerability of YMI024 in this patient population, with a focus on dose-finding.
YMI024 is being developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the Phase 2 clinical program evaluating YMI024 in patients with stable coronary artery disease and elevated hsCRP.
YMI024 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 2 trial is a dose-finding study evaluating efficacy, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP.
YMI024 is being studied in one Phase 2 clinical trial, NCT07830719, titled a dose-finding study to assess efficacy, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP. The trial is not yet recruiting and plans to enroll 180 participants.
The Phase 2 trial NCT07830719 is a randomized, double-blind, placebo-controlled dose-finding study of YMI024 in adults with stable coronary artery disease and elevated hsCRP. It plans to enroll 180 participants aged 18 years and older and is currently not yet recruiting.